文献速递淋巴瘤

泛SRC激酶抑制阻断非霍奇金淋巴瘤中的B细胞受体致癌信号

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
PubMed 文献 · Blood · 2018-03-22

研究利用弥漫性大B细胞淋巴瘤(DLBCL)患者来源的淋巴瘤细胞,检测靶向治疗对B细胞受体(BCR)信号的影响。在BTK抑制耐药的淋巴瘤中,阻断BTK活性增强了肿瘤对BCR下游替代致癌信号(汇聚于MYC上调)的依赖。遗传学和药理学抑制SRC激酶LYN、FYN和BLK可强烈减少患者来源DLBCL异种移植瘤和细胞系的生长,且不依赖分子亚型。

要点

  • 在DLBCL中,BCR激活促进多种致癌信号,对肿瘤增殖至关重要。
  • BTK抑制仅对部分DLBCL患者有效;BTK抑制耐药时肿瘤依赖BCR下游替代信号。
  • 抑制SRC激酶LYN、FYN和BLK可强烈减少DLBCL异种移植瘤和细胞系生长,不依赖分子亚型。

核心结论

  • 抑制SRC激酶LYN、FYN和BLK可完全消除BCR活性,并强烈减少DLBCL肿瘤生长,不依赖分子亚型,可能成为广泛DLBCL患者的相关治疗靶点。

研究设计与样本

  • 研究使用从DLBCL患者分离的淋巴瘤细胞,测量靶向治疗对BCR信号的影响并预测反应。

主要发现

  • 在BTK抑制耐药的淋巴瘤中,阻断BTK活性增强了肿瘤对BCR下游替代致癌信号的依赖,汇聚于MYC上调。
  • 遗传学和药理学抑制SRC激酶LYN、FYN和BLK可强烈减少患者来源DLBCL异种移植瘤和细胞系的肿瘤生长,不依赖分子亚型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In diffuse large B-cell lymphoma (DLBCL), activation of the B-cell receptor (BCR) promotes multiple oncogenic signals, which are essential for tumor proliferation. Inhibition of the Bruton's tyrosine kinase (BTK), a BCR downstream target, is therapeutically effective only in a subgroup of patients with DLBCL. Here, we used lymphoma cells isolated from patients with DLBCL to measure the effects of targeted therapies on BCR signaling and to anticipate response. In lymphomas resistant to BTK inhibition, we show that blocking BTK activity enhanced tumor dependencies from alternative oncogenic signals downstream of the BCR, converging on MYC upregulation. To completely ablate the activity of the BCR, we genetically and pharmacologically repressed the activity of the SRC kinases LYN, FYN, and BLK, which are responsible for the propagation of the BCR signal. Inhibition of these kinases strongly reduced tumor growth in xenografts and cell lines derived from patients with DLBCL independent of their molecular subtype, advancing the possibility to be relevant therapeutic targets in broad and diverse groups of DLBCL patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Battistello E, Katanayeva N, Dheilly E, et al. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. Blood. 2018. PMID: 29567799. doi:10.1182/blood-2017-10-809210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。